Molecular Mechanisms of Sulforaphane-Mediated Biofilm and Virulence Regulation of Streptococcus mutans

Authors

  • Tabark Ammar Middle Technical University, College of Health and MedicalTechniques/Baghdad, Iraq.
  • Mohameed Flyyiah Traef
  • Susan Zwyea

DOI:

https://doi.org/10.5195/d3000.2026.1492

Keywords:

Dental Caries, Tooth Loss, Biofilm, Dental Plaque

Abstract

Dental caries is the most prevalent biofilm-mediated disease worldwide, and Streptococcus mutans is its principal etiological agent. Because broad-spectrum antiseptics disturb the commensal flora and may drive resistance, anti-virulence strategies based on safe natural products are increasingly sought. Sulforaphane (SFN), a cruciferous isothiocyanate, has documented bacteriostatic activity, but its effect on clinical S. mutans isolates and on the molecular determinants of cariogenicity is poorly defined. Twenty-five clinical S. mutans isolates from carious lesions and dental plaque were challenged with SFN (Sigma-Aldrich) in 0.5% DMSO. Antibacterial activity was assessed by agar-well diffusion and broth microdilution (MIC/MBC) with chlorhexidine as positive control and triphenyltetrazolium chloride as viability indicator. Biofilm formation and the anti-biofilm effect were quantified by the crystal-violet microtiter assay. Expression of gtfC (EPS synthesis), ldh (acidogenicity) and sodA (oxidative-stress defense) was measured by qRT-PCR at sub-MIC (625 µg/mL) using 16S rRNA as reference gene (2-ΔΔCt method). SFN showed dose-dependent activity (zone of inhibition 17.8 ± 0.55 mm at 5%). The MIC was 1250 µg/mL for all isolates; no killing occurred up to 2500 µg/mL (MBC > 2500 µg/mL; MBC/MIC > 2), indicating a bacteriostatic, anti-virulence action. Eighteen isolates were strong, 3 moderate and 4 weak biofilm producers; SFN suppressed biofilm formation dose-dependently (p < 0.0001). At sub-MIC, SFN down-regulated gtfC by ≈99.5% (≈195-fold), sodA by ≈97.2% (≈35-fold) and ldh by ≈97.0% (≈34-fold) (all p < 0.01). gtfC/sodA expression was strongly correlated (r = 0.72), and PCA cleanly separated treated from untreated profiles (PC1 = 70.8%). SFN is a bacteriostatic, multi-target anti-virulence agent against clinical S. mutans, simultaneously disabling biofilm scaffolding, acidogenesis and oxidative-stress defense without killing the cell — a profile favorable for caries control with low resistance-selection pressure.

Downloads

Published

2026-08-14

Issue

Vol. 14 No. 2 (2026)

Section

Infancy & Adolescence

License

Copyright (c) 2026 Tabark Ammar, Mohameed Flyyiah Traef, Susan Zwyea

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.